2K3 Stock Chart & Stats
€14.20
€0.10(0.71%)
At close: 4:00 PM EDT
€14.20
€0.10(0.71%)
Day’s Range― - ―
52-Week Range€9.65 - €17.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€682.73M
Enterprise Value€453.48
Total Cash (Recent Filing)€144.68M
Total Debt (Recent Filing)€7.35M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 03, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,349,280
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.28Price Target Upside42.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€203.34M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsSustained ~79–80% gross margins indicate durable per‑procedure economics for iFuse implants. High margins provide a structural cushion against pricing and mix shifts, fund R&D and commercialization, and improve the path to operating leverage as volume scales over the next 2–6 months.
Strong Liquidity And Low LeverageVery low debt and a sizeable cash balance create a durable financial runway to fund launches, Smith & Nephew rollout, and planned CapEx without immediate refinancing. This reduces solvency risk and gives management flexibility for commercial investments over the medium term.
Commercial Momentum And Guidance UpgradeConsistent physician adoption (20 quarters of double‑digit growth) and territory productivity growth show scalable commercial traction for recurring implants. The guidance raise reflects accelerating demand and supports durable revenue expansion as new partnerships and launches contribute later in the year.
Bears Say
Ongoing GAAP Losses And Negative FCFDespite improving adjusted EBITDA and narrowed net loss, the company remains GAAP unprofitable with negative free cash flow. This persistent cash burn constrains self‑funding, may require continued reliance on cash reserves or financing, and limits margin of error during execution hiccups.
Execution / Timing Risk On Partner Ramp And LaunchesMaterial near‑term growth is contingent on phased partner rollouts, distributor onboarding and hospital approvals. Delays in training, capacity or seasonal trauma volumes could defer revenue and postpone breakeven, making growth and cash outcomes sensitive to execution over the coming months.
ASP Pressure And Near-Term CapEx/Investment NeedsMix shifts toward procedures that use fewer implants and trauma introductions imply modest ASP headwinds. Coupled with planned HQ and instrument CapEx, this increases near‑term cash variability and could compress realized margins until volume scale and mix normalize.
2K3 FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was €9.65 and its highest was €17.90 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is €682.73M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Aug 03, 2026 which is today.
How were SI-Bone Inc’s earnings last quarter?
Currently, no data Available
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.13.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,349,280 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in DE:2K3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.28 (42.84% Upside)
€20.28 (42.84% Upside)
Blogger Sentiment
Bullish
DE:2K3 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €443.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
2K3 Company Deck
2K3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum: double-digit top-line growth, industry-leading gross margins (~79.8%), improving profitability (Adjusted EBITDA up >440%), record physician engagement, multiple product launches, and a meaningful potential reimbursement tailwind from proposed CMS DRG changes. These positives are balanced by remaining GAAP net losses, negative free cash flow (though improved), near-term cash flow variability from HQ buildout and CapEx, and execution/timing risks around partner rollouts and ASP mix pressure. On balance, the strength in growth, margins, guidance raise, product pipeline, and reimbursement outlook outweigh the execution and timing headwinds.View all DE:2K3 earnings summaries2K3 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€20.28
▲(42.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










